A recent study has demonstrated that a precision medicine approach improves treatment selection for patients with soft tissue ...

A study conducted by researchers from the Agency for Science, Technology and Research (A*STAR), National Cancer Centre Singapore (NCCS) and National University of Singapore (NUS), in collaboration ...

Researchers used precision medicine platform, Quadratic Phenotypic Optimisation Platform (QPOP), to predict treatment response and identify effective drug combinations for soft tissue sarcomas (STS).

Natera has announced findings from a study evaluating its personalised tumour-informed molecular residual disease (MRD) test, ...

A study conducted by researchers from the Agency for Science, Technology and Research (A*STAR), National Cancer Centre Singapore (NCCS ...

Natera has announced findings from a study evaluating its personalised tumour-informed molecular residual disease (MRD) test, Signatera, in individuals with soft tissue and bone sarcomas.

Natera, Inc. , a global leader in cell-free DNA and precision medicine, today announced the results of a study led by Stanford University School of Medicine for the evaluation of Signatera, Natera's ...